Sandrine Piret-Gerard

Sandrine Piret-Gerard is currently the Senior Vice President of US Commercial at Gilead Sciences, not at Novartis Oncology as mentioned in the query.1 She has been in this role since February 2022, leading the organization responsible for commercializing all Gilead therapies in the US, delivering $18Bn revenue and impacting 1.9 million patients annually.1

Previously, Sandrine held the position of Senior Vice President and Head, Global Marketing, Value & Access at Novartis Oncology from March 2020 to January 2022.1 In this role, she led the Global Commercial functions for Novartis Oncology's marketed therapies and pipeline assets.1

Sandrine has an extensive career in the pharmaceutical industry, having held various leadership positions at companies such as Novartis, Sandoz, and the Boston Consulting Group.1 Her experience spans across different therapeutic areas, including oncology, hematology, neurosciences, and specialty medicines.1

Career Highlights

• Current Role: Senior Vice President, US Commercial at Gilead Sciences (February 2022 - Present)1
• Previous Roles:
  • Senior Vice President and Head, Global Marketing, Value & Access at Novartis Oncology (2020-2022)1
  • Vice President and Head, US Hematology at Novartis Oncology (2018-2020)1
  • Vice President and Head, US Solid Tumors at Novartis Oncology (2017-2018)1
  • CEO Hexal AG & Country Head Sandoz Germany (2014-2017)1

Achievements and Recognition

Sandrine has received several honors, including:

• Named one of the "40 under 40 in Business" by CAPITAL in July 20141
• Recognized as one of the "40 above 40 The World Most Inspiring Women" by F10 Fe & CapGemini Invent in March 20221
• Selected as a "2024 HBA Luminary" by the Healthcare Business Women Association in May 20241

Sandrine is multilingual, with professional proficiency in Dutch and German, and native or bilingual proficiency in English and French.1